C4 Therapeutics, Inc Share Price

NASDAQ: CCCC

Small Cap

$3.58

+0.92

(+34.40%)

as on September 16, 2025 at 1:29 am IST

$₹

C4 Therapeutics, Inc Stock Performance

as on September 16, 2025 at 1:29 am IST

Day's Low
Day's High
$2.79
Day's Price Range
$3.65
$3.58
22.07%
Downside
1.96%
Upside
52 Week's Low
52 Week's High
$1.09
52-Week Price Range
$7.14
$3.58
69.69%
Downside
99.44%
Upside

C4 Therapeutics, Inc share price movements today

Previous Close: $2.66
Open: $2.85
Volume: 8.5M
Day's Low - High: $2.79 - $3.65
52 Week Low - High: $1.09 - $7.14

C4 Therapeutics, Inc Historical Returns

1 Month Return: + 8.13 %
3 Month Return: + 58.33 %
1 Year Return: -58.7 %
3 Year Return: -76.58 %
5 Year Return: 0 %

C4 Therapeutics, Inc Stock Fundamentals & Key Indicators

Check C4 Therapeutics, Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$189.3M

EPS (TTM)

-1.512

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.13

Industry PE ratio

-3.8535542168674697

P/B Ratio

PEG Ratio

EBITDA

-121.6M

Revenue (TTM)

34.2M

Profit Margin

0.00%

Return On Equity TTM

73059000.00%

C4 Therapeutics, Inc Stock Valuation

Track how C4 Therapeutics, Inc P/E has moved over time to understand its valuation trends.

C4 Therapeutics, Inc in the last 5 years

Overview
Trends

Lowest (0.00x)

September 15, 2025

Today (-4.13x)

September 15, 2025

Industry (-3.85x)

September 15, 2025

Highest (-0.86x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: -4.13x

C4 Therapeutics, Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of C4 Therapeutics, Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
C4 Therapeutics, Inc	BUY	$189.3M	NA	-4.13	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	256.98%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.1B	47.85%	28.07	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	-3.43%	14.11	31.37%

Stock Returns calculator for C4 Therapeutics, Inc Stock including INR - Dollar returns

The C4 Therapeutics, Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

C4 Therapeutics, Inc investment value today

Current value as on today

₹60,575

Returns

₹39,425

(-39.42%)

Returns from C4 Therapeutics, Inc Stock

₹44,410 (-44.41%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on C4 Therapeutics, Inc Stock

Based on 15 analysts

BUY

73.33%

Buy

26.67%

Hold

0.00%

Sell

Based on 15 analysts, 73.33% of analysts recommend a 'BUY' rating for C4 Therapeutics, Inc. Average target price of $14.5

C4 Therapeutics, Inc Share Price Target

Get share price movements and forecasts by analysts on C4 Therapeutics, Inc.

What analysts predicted

75.31%UPSIDE

Target Price

$14.5

Current Price

$3.58

Analyzed by

15 Analysts

Target

$14.50

C4 Therapeutics, Inc target price $14.5, a slight upside of 75.31% compared to current price of $3.58. According to 15 analysts rating.

C4 Therapeutics, Inc Stock's Interest Amongst Investors

Search interest for C4 Therapeutics, Inc Stock has decreased by -11% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 17, 2025 to September 16, 2025

Change:-11% versus previous 30 day period

C4 Therapeutics, Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	3	2	11	3	3	12	15	5	7	6
Gross Profit	1	0	9	1	1	9	13	3	7	6
Operating Income	-36	-37	-27	-37	-32	-21	-28	-37	-29	-28
EBITDA	-32	-33	-23	-32	-26	-15	-22	-32	-28	-28
Interest Expense	0	0	0	2	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-34	-35	-26	-34	-28	-17	-24	-34	-26	-26
Income Tax Expense	0	1	-1	0	-2	-2	-2	0	-	-
Net Income	-33	-35	-27	-34	-28	-17	-24	-34	-26	-26
Net Profit Margin	-902.85%	-1348.42%	-244.19%	-1065.75%	-933.23%	-147.56%	-160.57%	-667.82%	-363.66%	-402.60%

C4 Therapeutics, Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	19	21	33	45	31	20	35
Gross Profit	-9	-26	-45	42	23	13	35
Operating Income	-16	-35	-60	-82	-129	-139	-119
EBITDA	-15	-30	-62	-78	-124	-122	-103
Interest Expense	-	2	1	2	2	1	-
Depreciation	1	1	1	1	1	1	1
Income Before Tax	-15	-33	-66	-83	-128	-131	-105
Income Tax Expense	0	0	0	2	-1	1	0
Net Income	-15	-34	-66	-83	-128	-132	-105
Net Profit Margin	-81.14%	-159.48%	-199.83%	-183.23%	-412.19%	-638.34%	-295.96%

C4 Therapeutics, Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-35	-27	-34	-28	-17	-24	-34	-26	-26
Operating Cash Flow	-18	-30	-24	-18	-4	-24	-17	-33	-12
Investing Cash Flow	15	57	31	-53	-11	0	13	29	38
Financing Cash Flow	0	-10	57	34	0	10	0	0	-
Change in Cash	-4	16	65	-36	-16	-13	-4	-4	26

C4 Therapeutics, Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-34	-66	-83	-128	-132	-105
Operating Cash Flow	55	-67	-86	-105	-106	-65
Investing Cash Flow	-1	-190	-189	58	158	-51
Financing Cash Flow	0	348	171	1	45	45
Change in Cash	54	91	-104	-46	97	-71

Global Institutional Holdings in C4 Therapeutics, Inc

Funds	Holdings
Soleus Capital Management, L.P.	9.83%
Orbimed Advisors, LLC	9.62%
Wasatch Advisors LP	9.47%
BlackRock Inc	7.44%
Morgan Stanley - Brokerage Accounts	5.7%

See all

Insights on C4 Therapeutics, Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 3 months, CCCC stock has moved up by 58.3%
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -34.57M → -26.02M (in $), with an average increase of 16.3% per quarter
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 134.3%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.5% return, outperforming this stock by 200.1%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 7.23M → 6.46M (in $), with an average decrease of 10.7% per quarter

About C4 Therapeutics, Inc

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.

Organisation	C4 Therapeutics, Inc
Headquarters	490 Arsenal Way, Watertown, MA, United States, 02472
Industry	Health Technology
CEO	Mr. Andrew J. Hirsch M.B.A.
E-voting on shares	Click here to vote

Key Management of C4 Therapeutics, Inc

Name	Title
Ms. Kelly A. Schick	Chief People Officer
Mr. Andrew J. Hirsch M.B.A.	CEO, President & Director
Dr. Kenneth C. Anderson M.D., Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board
Ms. Kendra Adams	CFO & Treasurer
Dr. Leonard M. J. Reyno M.D.	Chief Medical Officer
Mr. Mark Mossler	Chief Accounting Officer
Ms. Courtney Solberg	Senior Manager of Investor Relations
Ms. Jolie M. Siegel J.D.	Chief Legal Officer & Corporate Secretary
Dr. Nathanael S. Gray Ph.D.	Co-Founder & Member of Scientific Advisory Board
Ms. Paige Mahaney Ph.D.	Chief Scientific Officer

FAQs

What is C4 Therapeutics, Inc share price today?

C4 Therapeutics, Inc share price today is $3.58 as on September 16, 2025 at 1:29 am IST at the close of the market. C4 Therapeutics, Inc share today touched a day high of $3.65 and a low of $2.79.

What is the 52 week high and 52 week low for C4 Therapeutics, Inc share?

C4 Therapeutics, Inc share touched a 52 week high of $7.14 on October 16, 2024 and a 52 week low of $1.09 on April 9, 2025. C4 Therapeutics, Inc stock price today i.e. September 16, 2025 at 1:29 am IST is closed at $3.58,which is 49.86% down from its 52 week high and 229.95% up from its 52 week low.

What is C4 Therapeutics, Inc's market capitalisation today?

C4 Therapeutics, Inc market capitalisation is $0.00T as on September 16, 2025 at 1:29 am IST.

How to invest in C4 Therapeutics, Inc Stock (CCCC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for C4 Therapeutics, Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in C4 Therapeutics, Inc Shares that will get you 0.4190 shares as per C4 Therapeutics, Inc share price of $3.58 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy C4 Therapeutics, Inc Stock (CCCC) from India?

Indian investors can start investing in C4 Therapeutics, Inc (CCCC) shares with as little as ₹88.141 or $1 (as of September 16, 2025 at 1:39 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in C4 Therapeutics, Inc stock (as per the Rupee-Dollar exchange rate as on September 16, 2025 at 1:39 am IST). Based on C4 Therapeutics, Inc share’s latest price of $3.58 as on September 16, 2025 at 1:29 am IST, you will get 2.7933 shares of C4 Therapeutics, Inc. Learn more about fractional shares .